Clinical Trials Logo

Clinical Trial Summary

Influenza is associated with an increased risk for serious illness, hospitalization and death in pregnant women and young infants. The investigators estimated the effectiveness of a quadrivalent inactivated influenza vaccine (QIV) in pregnant women and their infants in 2019-2020 influenza season. Women were activelly followed during the influenza season on a weekly basis through telephone call in order to collect data about the onset of fever and/or respiratory symptoms by them or their young infants. Polymerase chain reaction testing in pharyngeal samples was offered to pregnant women and infants with influenza-like illness (ILI). A total of 636 pregnant women and 474 infants were studied. A Bayesian beta-binomial model was used.


Clinical Trial Description

Study period: Influenza 2019-2020 season The investigators followed actively the pregnant women and their infants in order to collect prospectively data on a weekly basis through phone calls during the entire influenza season. Definitions: - ILI was defined as the sudden onset of symptoms and fever, malaise, myalgia or headache, and cough, sore throat or shortness of breath. - ARI was defined as the presence of at least one respiratory symptom, regardless of fever. - Febrile episode was defined as the presence of fever only. - Fever was defined as a temperature of 38.0 C in at least two measurements within 24h. - The diagnoses of pneumonia and AOM were accepted as reported by the physicians who provided care to the women or their infants. The 2019-2020 QIV Vaxigrip-Tetra was used to vaccinate pregnant women. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04723771
Study type Observational
Source University of Athens
Contact
Status Completed
Phase
Start date September 1, 2019
Completion date August 31, 2020

See also
  Status Clinical Trial Phase
Completed NCT02988739 - Comparison of Laser Assisted Epidermal to Intradermal Administration of Seasonal Influenza Vaccine Phase 1